“Add stress balls to the list of innocuous items that have landed innocent citizens in jail due to shoddy police work and unreliable drug field tests.
The U.S. Court of Appeals for the 11th Circuit ruled last week that two Atlanta police officers are not entitled to qualified immunity from a civil lawsuit brought against them by Ju’zema Goldring for malicious prosecution. Goldring says the officers falsely accused her of jaywalking and cocaine trafficking, based on a field test of a powdery substance inside a stress ball she had in her purse.
Goldring spent nearly six months in the Fulton County jail because she couldn’t afford bail and told local news outlet NBC 46 that she was occasionally put in solitary confinement. What’s more, she was left in jail for four months after a crime lab concluded that the mysterious powder was sand, not cocaine.
According to the 11th Circuit’s opinion, Atlanta police officers Vladimir Henry and Juan Restrepo stopped Goldring on October 10, 2015, for allegedly jaywalking. Goldring claims she wasn’t jaywalking. In any case, the officers took Goldring to the police station and proceeded to cut open a stress ball they found in her purse and test the powdery substance inside using a Nark II field test for drugs.
As Reason reported earlier this year, such drug field test kits are manufactured by several different companies and are used by police departments and prison systems across the country. The test kits use instant color reactions to indicate the presence of certain compounds found in illegal drugs, but those same compounds are also found in dozens of known licit substances. And although the tests are fairly simple to use, they’re still prone to user error and misinterpretation.”
“Since 2014, state and local governments have filed thousands of lawsuits against pharmaceutical companies they blame for causing the “opioid crisis” by exaggerating the benefits and minimizing the risks of prescription pain medication. The theory underlying these cases is pretty straightforward: Drug manufacturers lied, and people died.
Two recent rulings—one by a California judge, the other by the Oklahoma Supreme Court—show how misleading this widely accepted narrative is. Both decisions recognize that undertreatment of pain is a real problem and that bona fide patients rarely become addicted to prescription opioids, let alone die as a result.”
“Democrats have a multi-pronged strategy for addressing drug prices in the Build Back Better Act. First, they would allow Medicare to negotiate with pharmaceutical manufacturers on the prices of a certain number of prescription drugs, something they have been promising to do for years. But Democrats also want to limit drug companies’ ability to hike the prices of their medications for everyone — regardless of what kind of health insurance they have — in the future.
To do that, Congress has proposed requiring drugmakers to pay rebates for any price increases, in either the Medicare health program or the commercial health plans that cover 180 million Americans.
But, as Politico reported this week, the plan to apply the inflation-indexed rebates to the commercial market could be in trouble.
Senate Republicans — at the urging of the drug industry — plan to challenge whether the rebates for commercial health plans are permissible in a bill passed through the budget reconciliation process.”
…
“the Byrd Rule requires that all the provisions in a budget reconciliation bill directly change federal spending or revenue.
Republicans will argue that the purpose of the provision is to control drug prices for the private plans, full stop, and that does not have anything to do with federal spending or revenue — at least not directly.
The Democratic counterargument would be that applying these rebates to commercial plans would have a serious, more than incidental, effect on the federal budget. The federal government subsidizes almost all private insurance plans in one way or another, and so lower or higher costs for those plans could have major implications and lower costs for private health plans could also mean higher wages for workers, who would then pay more in taxes.
Who wins is likely ultimately a decision for the Senate parliamentarian.”
…
“what would happen if the parliamentarian determines rebates covering commercial plans cannot be allowed under the Byrd Rule?
The big fear, voiced by advocates of the Democrats’ plan, is that drug companies would extract higher prices from the commercial market in order to make up for the revenue they would lose from Medicare once that program’s new price controls take effect.
According to several experts, that appears unlikely. Loren Adler, associate director of the USC-Brookings Schaeffer Initiative for Health Policy, covered why in a lengthy analysis published in September.
“Fundamentally, for this to occur, it would have to be the case that drug companies are benevolently choosing not to profit-maximize at present,” Adler told me this week, “which I find rather difficult to believe.””
…
“Under the current plan, drugmakers would pay a rebate based on their sales volume in both the Medicare and commercial markets. In that scenario, there would be little reason to raise list prices faster than inflation, because you are paying the penalty based on the entire market.
But if those rebates can’t include the commercial market, the penalty will be based on the Medicare market only — making it a smaller price to pay if a company does decide to hike the list price of a drug at a rate higher than inflation.”
“Mitch McConnell didn’t know what he was doing when he passed the 2018 Farm Bill. The bill included his provision that legalized industrial hemp, a form of cannabis that can be made into a wide variety of products including cannabidiol, a non-intoxicating cannabis compound commonly called CBD. That part was intentional — the law quickly launched a multi-billion dollar industry that put the once-obscure CBD compound into lattes, seltzers and hundreds of CVS stores across the country.
But after three years it appears one of the law’s biggest impacts was entirely unintentional: It accidentally created a booming market for synthetic THC, marijuana’s primary intoxicant.
The same type of CBD that’s for sale at CVS is now being synthetically converted into THC and packaged into vape cartridges and gummy bears. Thanks to a loophole in the 2018 Farm Bill, these drugs are marketed as a “legal high” and sold online and in states where marijuana remains illegal.
But chemists warn that these drugs can contain hazardous solvents, acids and unknown compounds. When FiveThirtyEight legally purchased hemp-derived THC products for testing, we found illegal levels of THC and a variety of mystery compounds that could not be identified. There are no federal safety testing requirements for these products, and while hemp companies occasionally publish test results, some brands have been caught using fake test documents.”
…
“The hemp industry has quickly moved past selling just Delta-8-THC and is now offering an increasingly long list of synthetic cannabinoids that they can ship directly to your door.”
…
“McConnell has spent years fighting for hemp legalization and, in particular, the legalization of CBD in an effort to appease his home state’s farmers. He made hemp legalization a campaign issue in 2013 and, when the Drug Enforcement Agency blocked Kentucky’s farmers from growing CBD-rich hemp under an earlier pilot program, the senator publicly fought the agency until the DEA backed down.
When it came to writing the 2018 law, McConnell apparently didn’t want to take any chances with the DEA. His provision permanently removed hemp from the Controlled Substance Act”
…
“The five professional chemists we spoke to for this piece were all particularly concerned by the sale of synthetic cannabinoids like Delta-8-THC-O acetate, which are both synthetically made and synthetically designed (unlike Delta-8-THC, which can be found naturally in cannabis). These types of synthetic cannabinoids were first invented by the pharmaceutical industry and can react with our internal cannabinoid receptors in unnaturally strong ways.”
“A 2020 meta-analysis of 26 randomized controlled trials concluded “there is moderate-certainty evidence that [e-cigarettes] with nicotine increase quit rates compared to [e-cigarettes] without nicotine and compared to nicotine replacement therapy.” The results of population studies, Balfour et al. say, “are consistent with a near doubling of quit attempt success, found in the randomized controlled trials, and the fact that e-cigarettes are smokers’ most used aid in quit attempts.” They also note that declines in U.S. cigarette sales accelerated sharply as sales of vaping products took off, which reinforces the impression that more vaping means less smoking.”
“Indian officials said..they had seized nearly three tonnes of heroin originating from Afghanistan worth an estimated 200 billion rupees ($2.72 billion) amid the chaos following last month’s takeover of the country by the Taliban.”
“some states legalized it, hoping to put an end to the black market. But legalization hasn’t ended the violence.
Why? Because many states impose so many unnecessary rules.
California is one of the worst.
“The illicit market is approximately two to three times the size of the legal market,” says cannabis industry lawyer Tom Howard in my new video.
Illegal sales thrive in California because politicians make distribution pointlessly difficult.
Howard advises clients who want to open a dispensary, “You have to have a $50,000 safe, a $200,000 security system, and a $100,000 consultant help you make an 800-page application.”
Every single plant must be weighed, tagged, and tracked from seed to sale.
This information is “not being used to benefit anybody,” complains grower Jason Downs. “It’s just a waste of everybody’s time, money.”
While legal sellers struggle, clueless California Gov. Gavin Newsom complains: “Illegal cannabis grows! They’re getting worse, not better.”
His solution: California taxpayers now will spend $100 million to bail them out!”
…
“Illinois’ rules are probably the worst.
“Only ‘social equity veterans’ in Illinois can get a license,” explains Howard. In other words, new licenses are supposed to go to prior “victims of the drug war.”
But the bureaucrats’ rules are so complex that a full year after legalization, zero new licenses have been issued.
Meanwhile, politically connected people grabbed every existing license.
One billionaire from the Wrigley gum family “paid $155 million for six dispensary licenses,” says Howard. Illinois is “creating a cartel.””
…
“Other states have bad rules, too.
“Florida and Arizona are millionaires’ clubs,” says Howard. “You have to not only grow it; you have to be able to produce it and process it. You have to own your own dispensary. If you have $40 or $50 million, it’s great.”
Massachusetts requires all dispensaries to black out windows lest anyone see the marijuana. Stores must also check everyone’s IDs multiple times.
Legalization doesn’t have to be stupid.
Oregon and Colorado have reasonable rules, and in Oklahoma, “anyone can get a cannabis license,” says Howard, “provided you’ve lived in Oklahoma for two years.”
The result?
“You get a lot more innovation—more entrepreneurs coming into market. Some go out of business, and some do very well….It’s free market capitalism.”
“Substantially reducing the doses of pain medication prescribed for patients on long-term opioid therapy is associated with a threefold increase in suicide attempts and a 69 percent increase in overdoses, according to a study published this week in The Journal of the American Medical Association (JAMA). The study reinforces concerns that the “tapering” encouraged by federal guidelines as a response to the “opioid crisis” causes needless suffering among patients, leading to undertreatment of pain, withdrawal symptoms, and emotional distress.”
…
“Although the CDC’s advice was not legally binding, and although the guidance said doses should be tapered only when medically appropriate, doctors, lawmakers, insurers, and pharmacies interpreted the agency’s warnings about daily doses exceeding 90 MMEs as a hard limit. “These and other widely disseminated recommendations have led to increased opioid tapering among patients prescribed long-term opioid therapy,” Agnoli et al. note.”
…
“The CDC is mulling revisions to its advice. “A revised CDC Guideline that continues to focus only on opioid prescribing will perpetuate the fallacy that, by restricting access to opioid analgesics, the nation’s overdose and death epidemic will end,” Mukkamala warned in his letter to the CDC. “We saw the consequences of this mindset in the aftermath of the 2016 Guideline. Physicians have reduced opioid prescribing by more than 44 percent since 2012, but the drug overdose epidemic has gotten worse.””
“After years of steadily moving in tandem, two of America’s worst public health trends diverged during the coronavirus pandemic.
Drug overdose deaths jumped 30 percent last year to 92,500, according to newly released federal data, a sudden surge following years of incremental increases once the opioid epidemic took hold. But suicides actually dropped slightly, from 47,500 in 2019 to 44,800 in 2020.
Those two trends have tracked closely over the past decade, so much so that there is an umbrella term in academia that encompasses both of them (among other things): deaths of despair. Much of the recent stagnation in US life expectancy can be explained by these premature deaths, concentrated especially among young men, and scholars have theorized about the economic and social conditions driving those trends.
That was the situation before Covid-19. So what happened during the pandemic?”